LEXX

Lexaria Bioscience Corp

1.08

0.02+1.89%

After Hours: 1.030 -0.05 -4.63%17:33 05/09 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE1.050/1.060

TODAY RANGE1.040-1.100

VOL94.59K

MARKET CAP21.04M

52 WEEK RANGE1.010-4.440

AVG VOL (3M)110.68K

% TURNOVER0.49%

TURNOVER--

P/E (TTM)-1.8468

% RANGE5.66%

EPS(TTM)-0.5848

P/E(FORWARD)-1.8621

P/B2.654

BVPS0.4069

DIVIDEND--

P/S36.73

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP19.56M

SHARES OUTSTANDING19.48M

NEXT EARNINGS07/10-07/14

FREE FLOAT18.11M

LOT SIZE1

EX-DIV DATE01/12/2021

News

Press Releases

Financial Reports

Profile

TipRanks·04/28 20:37
Lexaria Bioscience Secures $2 Million in Direct Stock Offering
TipRanks·04/25 20:38
Lexaria Bioscience Secures $2 Million in Direct Stock Offering
Seeking Alpha·04/25 13:19
Lexaria Bioscience announces $2M registered direct offering; shares slip 19%
TipRanks·04/25 12:15
Lexaria Bioscience prices 2M shares at $1.00 in registered direct offering
TipRanks·04/23 14:37
Lexaria Bioscience: A Key Player in the Future of Oral GLP-1 Drugs
TipRanks·04/23 13:21
Lexaria provides GLP-1 update following industry developments
Reuters·04/14 21:01
Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary
Reuters·04/04 20:05
Lexaria Bioscience Corp <LEXX.OQ> expected to post a loss of 15 cents a share - Earnings Preview
Reuters·04/04 11:46
LEXARIA BIOSCIENCE CORP <LEXX.O>: MAXIM GROUP CUTS TARGET PRICE TO $6 FROM $12
TipRanks·04/03 15:08
Lexaria Completes Enrollment for Pioneering Drug Delivery Study
TipRanks·04/03 13:20
Lexaria Bioscience provides update on ongoing human study GLP-1-H24-4
TipRanks·04/02 14:33
Lexaria Bioscience Begins Human Trials for Oral Liraglutide Alternative
TipRanks·04/02 13:15
Lexaria Bioscience begins dosing for GLP-1 study #5
TipRanks·02/27 16:09
Lexaria Bioscience Advances Strategy in GLP-1 Drug Sector
TipRanks·02/27 13:55
Lexaria Bioscience provides GLP-1 strategic update

Same Industry

Name/Symbol

Change%

Price

Lexaria Bioscience Corp

LEXX

+1.89%

1.08

McKesson

MCK

+0.47%

693.46

Biogen Inc

BIIB

-0.19%

118.17

Amgen Inc

AMGN

-2.28%

265.86

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+29.60%

0.0324

Shire

SHPG

179.20

Lilly Eli & Co

LLY

-2.25%

734.57

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

+4.29%

1.46

Johnson & Johnson

JNJ

-0.93%

154.22

Abbvie Inc

ABBV

-0.53%

184.60

Zoetis Inc

ZTS

-1.50%

159.27

Gilead Sciences Inc

GILD

-1.27%

96.91

Novo-Nordisk A/S

NVO

+1.42%

65.77

Bristol-Myers Squibb Co

BMY

-0.92%

46.45

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

-1.15%

22.28

Sanofi FR

SNY

-0.04%

49.90

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

-1.30%

108.70

Dr Reddys Labs

RDY

+1.67%

13.40

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.